Dauntless Investment Group LLC purchased a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma accounts for 3.0% of Dauntless Investment Group LLC's investment portfolio, making the stock its 2nd biggest holding. Dauntless Investment Group LLC owned about 5.88% of OKYO Pharma as of its most recent filing with the Securities & Exchange Commission.
Separately, FNY Investment Advisers LLC bought a new position in shares of OKYO Pharma in the first quarter valued at approximately $25,000. Institutional investors own 2.97% of the company's stock.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Monday, May 5th.
Get Our Latest Report on OKYO
OKYO Pharma Trading Up 14.4%
Shares of OKYO Pharma stock traded up $0.39 on Friday, hitting $3.09. The company had a trading volume of 684,755 shares, compared to its average volume of 171,796. The business has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $1.67. OKYO Pharma Limited Sponsored ADR has a 52 week low of $0.81 and a 52 week high of $3.11.
OKYO Pharma Company Profile
(
Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Read More
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access